AstraZeneca Can't Shed FCA Suit Over Seroquel 'Scheme'

Law360, New York (April 18, 2017, 5:23 PM EDT) -- A New York federal judge on Monday preserved a whistleblower's False Claims Act suit accusing AstraZeneca PLC of concealing safety information about antipsychotic drug Seroquel, finding plausible allegations of a "complex fraudulent scheme."

The ruling from U.S. District Judge Frederic Block kept alive portions of a 313-page FCA suit filed by Allison Zayas, a onetime sales contractor for AstraZeneca. It marked the first written explanation of a decision delivered orally almost three weeks ago.

At issue are Seroquel prescriptions reimbursed by Medicare from 1997 to 2009. Zayas alleges that Seroquel may pose cardiac risks and that AstraZeneca misrepresented the dangers of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!